Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study

• Status: Unknown status
• Trial end date: 2015-03-01

Summary

Among the psychiatric symptoms observed in the premotor phase of Parkinson's disease (PD) and/or in "de novo" patients, apathy is relatively frequent (estimated to 23%). However, the neuropathological bases of apathy are still unknown. However, recent data suggests that apathy could be linked to a more specific dopaminergic denervation in the ventral striatum.

Rasagiline increases the bioavailability of striatal endogenous dopamine by blocking the MAO-B. Some recent data suggest rasagiline could be effective to improve apathy in Parkinson's disease.

The primary outcome is to demonstrate a significant reduction of apathy using the Lille apathy rating scale (LARS) in drug naive patients with early diagnosed Parkinson's disease, using a treatment by rasagiline.

• Phase: Phase 4

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Collaborators: Centre Hospitalier de la côte Basque; Centre Hospitalier du Pays d'Aix; Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Saint Etienne; Centre Hospitalier Universitaire, Amiens; CHU de Rennes (Rennes); CHU Purpan (Toulouse); Fondation Rothschild Paris; H. Lundbeck A/S; H. Lundbeck A/S, TEVA; Hôpital de la Timone (MARSEILLE); Hôpital Dupuytren; Hôpital Haut-Lévêque; Poitiers University Hospital; University Hospital, Caen; University Hospital, Lille; University Hospital, Rouen
• Treatments: Rasagiline